Abstract:In a healthy host, a localized injury or infection generates an inflammatory response initiated by the site-specific recruitment of blood neutrophils ( 1 ). This begins a well-orchestrated series of cellular and humoral events that, over time, result in resolution and return to homeostasis. Under conditions of systemic or prolonged illness, including sepsis, this temporary regulated response becomes persistent and results in tissue accumulation of highly activated neutrophils that can cause collateral tissue damage with risk of organ failure ( 1–3 ). A significant component of tissue damage stems from the neutrophilic targeting of microvessels, which lose control of selective permeability that is essential to maintenance of organ function ( 4–7 ). Because of the importance of vascular function, together with the unmet need for therapeutic management of critical illness, finding new mechanisms that contribute to vascular damage by activated neutrophils is of basic and clinical relevance. Given the essential antimicrobial role neutrophils play during infection, the elimination of these cells or suppression of their function in order to protect from collateral damage is contraindicated in the septic patient. The challenge is to identify molecular targeting strategies that can attenuate the collateral damage caused by activated neutrophils yet preserve their benefit to immune defense.

Inhibition Of Integrin Vla-3 And Tetraspanin Cd151 Protects Against Neutrophil-Mediated Endothelial Damage